CeQur looks to treble workforce in Massachusetts

CeQur is looking to treble the size of its workforce in Massachusetts with an expansion of the plant in Marlborough it plans to use to make the PaQ insulin device it hopes to launch this year. PaQ, a patch-like device, is designed to deliver both basal insulin and on-demand bolus insulin over 3 days. CeQur says it’s optimized the device for high-volume, low-cost manufacturing ahead of the planned commercialization of the 2nd generation this year. The 1st-generation PaQ device won CE Mark approval in the European Union in November 2012. CeQur, which is based in Marlborough and Lucerne, Switzerland, said today that it’s expanding its Bay State home to 25,000 square feet later this year, and plans to take its workforce there from 50 to 150 employees over the next 2 years. “Over the past year, we’ve optimized PaQ for high-volume, low-cost manufacturing and continued to amass clinical evidence that demonstrate PaQ will offer a safe, simple-to-use and cost-effective alternative to daily insulin injections for people with Type II diabetes,” CEO Doug Lawrence said in prepared remarks. “We are excited to be expanding our facilities here in Marlborough in preparation for the market introduction of PaQ. “Marlborough has been our U.S. base since CeQur was founded, and we’ve been extremely pleased with the resources available to us here, as well as the support we’ve received from the robust Massachusetts life-sciences and me...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Diabetes Wall Street Beat CeQur SA Source Type: news